UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
AMENDMENT NO. 1 TO FORM 10-Q
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2002
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NUMBER 000-30929
KERYX BIOPHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 13-4087132
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER IDENTIFICATION NUMBER)
INCORPORATION OR ORGANIZATION)
101 MAIN STREET, 17TH FLOOR
CAMBRIDGE, MA 02142
(ADDRESS INCLUDING ZIP CODE OF PRINCIPAL EXECUTIVE OFFICES)
617-494-5515
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
Indicate by an (X) whether the registrant: (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes /X/ NO / /
As of July 30, 2002, the registrant had outstanding 19,907,185 shares of Common
Stock, $0.001 par value per share.
This Amendment No. 1 on Form 10-Q/A to the registrant's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2002 is being filed to
reflect a correction to the registrant's statement of its future operating needs
and cash expenditures. Paragraph 6 of "Liquidity and Capital Resources"
contained in Item 2 of the registrant's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2002 is hereby amended and restated in its entirety as
follows:
We believe that our $30.2 million in cash, cash equivalents, and
short-term securities as of June 30, 2002 will be sufficient to enable us to
meet our planned operating needs and capital expenditures until at least early
2005. Our cash and cash equivalents as of June 30, 2002 are invested in highly
liquid investments such as cash, money market accounts, short-term US corporate
debt securities, and short-term obligations of domestic governmental agencies.
As of June 30, 2002, we are unaware of any known trends or any known demands,
commitments, events, or uncertainties that will, or that are reasonably likely
to, result in a material increase or decrease in our required liquidity. We
expect that our liquidity needs throughout 2002 will continue to be funded from
existing cash, cash equivalents, and short-term securities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KERYX BIOPHARMACEUTICALS, INC.
Date: August 21, 2002 By: /s/ Ira Weinstein
-------------------------------------------
Ira Weinstein
Interim Chief Financial Officer & Treasurer
STATEMENT PURSUANT TO 18 U.S.C. SECTION 1350
Pursuant to 18 U.S.C. Section 1350, each of the undersigned certifies
that this Form 10-Q/A for the period ended June 30, 2002 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934
and that the information contained in this report fairly presents, in all
material respects, the financial condition and results of operations of Keryx
Biopharmaceuticals, Inc.
/s/ Benjamin Corn
-------------------------------------------
Date: August 21, 2002 Benjamin Corn, M.D.
Chief Executive Officer
/s/ Ira Weinstein
-------------------------------------------
Date: August 21, 2002 Ira Weinstein
Interim Chief Financial Officer & Treasurer